Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;6(12):1279-93.
doi: 10.2217/imt.14.90.

Past, present and future targets for immunotherapy in ovarian cancer

Carlton L Schwab  1 , Diana P English, Dana M Roque, Monica Pasternak, Alessandro D Santin
Affiliations
Review

Past, present and future targets for immunotherapy in ovarian cancer

Carlton L Schwab et al. Immunotherapy. 2014.

Abstract

Ovarian cancer is the leading cause of death from gynecologic malignancy in the US. Treatments have improved with conventional cytotoxic chemotherapy and advanced surgical techniques but disease recurrence is common and fatal in nearly all cases. Current evidence suggests that the immune system and its ability to recognize and eliminate microscopic disease is paramount in preventing recurrence. Ovarian cancer immunotherapy is targeting tumors through active, passive and adoptive approaches. The goal of immunotherapy is to balance the activation of the immune system against cancer while preventing the potential for tremendous toxicity elicited by immune modulation. In this paper we will review the different immunotherapies available for ovarian cancer as well as current ongoing studies and potential future directions.

Keywords: CA125; EpCAM; NY-ESO-1; WT-1; adoptive transfer; mesothelin; ovarian cancer; p53; tumor associated antigens; tumor vaccines.

PubMed Disclaimer

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012;62(1):10–29. - PubMed
    1. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003;348(3):203–213. - PubMed
    1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. - PubMed
    1. Lu J, Aggarwal R, Kanji S, et al. Human ovarian tumor cells escape gammadelta T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS ONE. 2011;6(9):e23348. - PMC - PubMed
    1. Thedrez A, Sabourin C, Gertner J, et al. Self/non-self discrimination by human gamma delta T cells: simple solutions for a complex issue? Immunol. Rev. 2007;215:123–135. - PubMed

Publication types